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Objective: To obtain a realistic overview of management and clinical outcomes of patients with venous thromboembolism
(VTE) in Spain on the basis of data from a national multicenter registry.
Methods: A prospective registry was initiated in Spain in March 2001. Data were collected from patients with objectively
confirmed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and entered into the online registry by
physicians who were responsible for the management of these patients.
Results: As of August 2002, 4011 patients with confirmed VTE were included in the registry: 60% with DVT, 23% with
PE, and 17% with both DVT and PE. Diagnostic methods for VTE included compression ultrasonography (86%),
venography (10%), V/Q lung scans (42%), computed tomography scan (28%), and pulmonary angiography (0.9%).
D-dimer testing was performed in 61% of cases and was positive in 92% of patients with confirmed VTE. The majority of
DVT (95%) were located in the lower extremities (82% proximal and 4% bilateral), while 4.8% were located in the upper
extremities or neck veins. Most patients (90.5%) were admitted to hospital. In the acute phase, treatment consisted of low
molecular weight heparin (LMWH) in 88%, unfractionated heparin (UFH) in 11%, and fibrinolysis in 0.8%. Cava filters
were inserted in 2% of patients, mainly because of active bleeding (13%), increased hemorrhagic risk (38%), or recurrent
VTE (29%). Absolute bed rest was recommended to 63% of patients. Secondary prevention of VTE included oral
anticoagulants (75%) and LMWH (24.5%). Therapeutic compression stockings were prescribed to 53% of patients at the
time of hospital discharge. Regarding the main clinical outcomes during an average (SD) follow-up period of 156 95
days, 19% had adverse events: 12.5% of patients died, 5.5% had clinically confirmed VTE recurrence, and 9.8% suffered
bleeding complications (44% with major bleeding).
Conclusions: This prospective observational multicenter registry provides a large database reflecting the actual day-to-day
clinical practice regarding VTE management in a European country. The most important findings were the increasing use
of spiral computed tomography for PE diagnosis, the unexpectedly high proportion of patients admitted to hospital
despite the use of LMWH in almost 90% of cases in the acute phase, and the utilization of LMWH for secondary
prevention in almost 25% of cases. On the other hand, this large-scale prospective registry permits on-line consultation of
high-risk situations to assess how difficult cases were treated and what their outcomes were. This will provide a most
useful tool for the practicing physician responsible for the management of VTE patients. (J Vasc Surg 2003;38:916-22.)
Venous thromboembolism (VTE) remains an impor-
tant cause of morbidity and mortality in western countries.
According to population-based studies conducted in North
America and Europe,1-4 the annual incidence of this disease
is between 1000 and 2000 per year, and more than one
third of these cases represent recurrent disease.3 A 25-year
population-based study has reported that although the
incidence of pulmonary embolism (PE) has decreased over
time, the incidence of deep vein thrombosis (DVT) remains
unchanged for men and is increasing for older women.5
The natural course of untreated VTE is unfavorable,
especially in patients with PE; in a trial performed in 1960,
approximately 25% of these patients died, whereas another
25% experienced nonfatal recurrent VTE .6 The introduc-
tion of anticoagulant therapy with heparin and warfarin has
substantially reduced the mortality and morbidity associ-
ated with this disorder, as shown by many randomized
controlled trials.7 However, inclusion of patients into con-
trolled studies entails a careful screening process that results
in the exclusion of patients at very high risk of developing
complications,8,9 as well as selection bias.
At the present time, there is limited information on
how patients with VTE are currently managed in Spain10,11
and how consistently the recommendations from clinical
trials are implemented in clinical practice. The National
Registry of Venous Thromboembolism in Spain or RIETE
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(Registro Informatizado de la Enfermedad TromboEm-
bo´lica) is an ongoing national, prospective, and observa-
tional study that, since March 2001, has tracked practice
patterns and outcomes of more than 4000 patients with
acute symptomatic VTE enrolled at 81 selected hospitals
throughout Spain.
METHODS
Objectives of the registry. The main objective of this
registry is to collect prospective data on the epidemiologic
characteristics, management, and outcomes of patients
with acute symptomatic VTE that can be used to (1) obtain
a realistic profile and overview of patients with VTE and
data on existing and evolving patterns in clinical practice in
the management of patients with this disorder; (2) identify
gaps between recommendations based on clinical trials and
real day-to-day practice; (3) locally assess individual hospi-
tal practice and outcomes to facilitate quality improvement;
and (4) create predictive models to assist physicians in
making decisions in difficult cases.
Registry design. The RIETE initiative is a national,
multicenter, prospective, and observational registry spon-
sored by Aventis Pharma (Madrid, Spain) that gathers and
analyzes data on patients with confirmed VTE (DVT or
PE) initially diagnosed in any of the 81 participating hos-
pitals, which represent approximately 8.8% of the 900
Spanish hospitals. These hospitals were selected by the
scientific advisory committee on the basis of the presence in
these institutions of physicians with experience in the man-
agement of VTE patients. These physicians were invited to
be local clinical coordinators for the study. Hospitals of all
levels and those distributed geographically in all Spanish
regions were included in the study.
Patient management is decided by the physicians with-
out any imposed intervention in order to collect data
reflecting the actual clinical approach to the management
of VTE. The database consists of different sections that
include patient demographics; symptoms upon presenta-
tion; presence of DVT, PE, or both; location of thrombi;
diagnostic methods used and their results; risk factors; and
treatment, in both the acute phase (first 10 days of therapy)
and for subsequent secondary prevention.
Outcomes. Main outcomes from March 2001 to Au-
gust 2002 were recurrent VTE, bleeding complications,
and mortality. All adverse events occurring during at least a
3-month follow-up period were analyzed. Local coordina-
tors at each participating hospital were responsible for the
3-month follow-up after VTE diagnosis. In most cases,
they reviewed the hospital charts and examined patients in
the outpatient clinic. If this was not possible, they talked to
the patients by phone and, when this was not feasible,
contacted their family physicians by phone, fax, or e-mail to
get reliable information on the development of adverse
events. After discharge, each patient was followed up by a
family physician and was contacted by letter or phone at 3
months.
Diagnostic studies were performed only in clinically
suspicious cases and not on selective cases or symptom-free
patients. Diagnosis of DVT was based on the absence of full
compression on venous ultrasound scan or on the presence
of a filling defect on venography. Diagnosis of PE was based
on high-probability ventilation-perfusion scan, spiral com-
puted tomography (CT), or contrast pulmonary angiogra-
phy. Recurrent DVT was defined as an extension of throm-
bus or development of new thrombus in a previously
unaffected vein segment detected by ultrasound scan or
venography. Recurrent PE was defined by the presence of
new segmental perfusion defects compared with the previ-
ous studies. Bleeding complications were classified as major
if transfusion of more than two units of packed red blood
cells was required, if the patient had to be admitted to
hospital for this reason, or if the patient’s life was at risk. As
this is an observational prospective registry, there is not a
central clinical events committee. However, all of the ad-
verse events (recurrent VTE, bleeding, and death) are
entered into the database by the coordinator at each hos-
pital and analyzed by the Study Coordinating Center.
Data collection. Patients with symptomatic, acute
DVT or PE confirmed by objective testing who meet the
predefined enrollment criteria are considered eligible for
inclusion into the registry. A registry coordinator at each
participating hospital records data from each patient onto a
computer-based case report form (CRF). They interact
with the physicians who are responsible for the manage-
ment of VTE patients and who have volunteered to partic-
ipate in the study. In addition, coordinators are instructed
to ensure that consecutive patients with confirmed VTE are
included in the registry. Once completed, the information
is transferred online to the Study Coordinating Center (S &
H Medical Science Service, Madrid, Spain) responsible for
all data management. Patient identities remain confidential
because they are identified by a unique number assigned at
the time of enrollment by the Study Coordinating Center.
The Study Coordinating Center is not connected in any
way with Aventis, which serves only as sponsor to the study
by means of an educational grant and does not have access
to the data. Data submitted through the Internet are sent
via a secure website. This website (http://www.riete.com)
is currently written in Spanish, but there are plans to
translate it into English in the near future.
The need to obtain informed consent from patients to
participate in the registry varies depending on the require-
ments of individual hospital ethics committees. Participa-
tion in the registry is voluntary, and hospitals are encour-
aged to enter consecutive patients with confirmed DVT
(venography, ultrasound scan, or plethysmography) or PE
(ventilation/perfusion lung scans, spiral CT angioscan, or
pulmonary angiography), irrespective of management
strategy and outcome. During the enrollment period, hos-
pitals are asked not to enter patients participating in clinical
trials, so that the registry will reflect actual clinical practice
rather than management mandated by a clinical trial proto-
col. Patients for whom a 3-month follow-up would not be
possible are also excluded.
Quality control. Before entering data into the regis-
try, the clinical coordinator at each participating hospital
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receives a training manual explaining how to complete the
CRF and how to define each variable. Periodic meetings of
registry coordinators, members of the Study Coordinating
Center, and a scientific advisory committee are held.
Data quality is monitored electronically to detect ab-
normal variables, inconsistencies, and errors, and questions
are either sent via e-mail or telephoned to the local coordi-
nators for resolution. In addition, full audits are periodi-
cally performed.
Statistical methods. Differences between groups are
assessed by the 2 test or Fisher exact test for categorical
variables and by the two-sided t test for continuous vari-
ables. For all analyses, a two-tailed P value of less than .05 is
considered to indicate statistical significance.
RESULTS
From March 2001 to August 2002, 4011 patients with
confirmed symptomatic VTE were enrolled from 81 con-
tributing hospitals throughout Spain. Enrollment contin-
ues and is currently proceeding at a rate of approximately
300 new patients per month. Of the 4011 consecutive VTE
patients included in the registry, 2017 (50.3%) were
women and 1994 (49.7%) were men. The average age was
66 17 years, and weight and height were 74 14 kg and
164  9 cm, respectively.
To date, 2402 patients (60%) were found to have
isolated DVT, 922 (23%) were found to have isolated PE,
and 687 (17%) were found to have both PE and DVT. The
most common signs and symptoms upon presentation to
hospital were limb swelling and pain for DVT and dyspnea
and chest pain for PE. Among patients with confirmed PE
without DVT symptoms, a diagnostic test for DVT was
performed in 54% and had positive results in 36%. On the
other hand, among patients with confirmed symptomatic
DVT without symptoms of PE, a diagnostic test for PE was
completed in 16% and confirmed the presence of PE in
30%.
At the time of VTE diagnosis, 264 patients (6.6%) were
inpatients and the remaining 3747 (93.4%) were outpa-
tients. Of these, 3394 (90.5%) were admitted to hospital
and 353 (9.5%) were discharged from the emergency de-
partment without hospital admission. Table I shows the
proportion of patients admitted and discharged and the
final diagnosis.
Thrombi were located in the lower extremities in 2941
cases (95.2%) and in the upper extremities in 148 patients
(4.8%). Among those with leg DVT, 55% were in the left
limb, 42% were in the right limb, and 3% were bilateral. In
the upper extremities, 50% were located in the right arm,
45% in the left arm, and 5% were bilateral (P  .05).
Forty-one percent of upper-extremity DVTs were related
to the presence of a central catheter, and 29% were consid-
ered idiopathic. Among patients with leg DVT, 82.5% were
proximal (affecting the popliteal, femoral or iliac veins) and
17.5% were limited to the calf veins.
Ventilation-perfusion lung scanning was performed in
1246 patients (31%) with suspected PE. The results were
high probability in 63%, nondiagnostic in 27%, and normal
in 10%. Spiral CT was performed in 821 cases (20%) and
was high probability for PE in 87%. Conventional contrast
pulmonary artery angiography was completed in 27 pa-
tients (0.6%) and was considered high probability in 81.3%.
Ultrasound scanning of the lower or upper extremities
was done in 3270 patients (81%) and was diagnostic for
DVT in 87%. Venography was performed in 338 patients
(0.8%) and confirmed DVT in 91%. Impedance plethys-
mography was used in 16 cases (0.4%) for diagnosis.
D-dimer was analyzed in 2263 patients (56%) with
confirmed VTE and was positive in 2087 (92.2%) and
negative in 176 cases (7.8%). D-dimer was positive in 79.3%
of patients with upper extremity DVT and in 93.3% in those
with leg DVT (P  .001). Approximately 10 different
D-dimer tests were used in the participating hospitals; 56%
were based on immunologic assays and 44% on agglutina-
tion techniques.
The main risk factors detected in patients with con-
firmed VTE (PE, DVT, or both) were immobilization
lasting more than 4 days in the previous 2 months (31%),
cancer (20.5%), varicose veins (20%), history of VTE
(17.5%), surgery in the past 2 months (14.6%), travel by
plane or car lasting longer than 6 hours in the past 3 weeks
(0.9%), estrogen therapy (6.1%), pregnancy (5%), postpar-
tum (5.5%), and known thrombophilia (2.1%). The main
reasons for nonsurgical immobilization were neurologic
problems (7%), lower extremity trauma (5%), acute infec-
tion (3.5%), respiratory problems (3%), and cancer (2%).
Table II. Risk factors in patients with upper- and lower-
extremity deep vein thrombosis
Lower-
extremity
Upper-
extremity P
Age 66  2 55  3 .001
Immobility 31% 14% .001
Cancer 20% 32% .01
Colorectal 14% 14.4% .8
Breast 28% 45% .11
Lung 8% 18.5% .02
Prostate 21% 15% .38
Surgery 13.3% 13.9% .83
Previous VTE 18.7% 5.4% .01
Estrogens 5.5% 13% .05
Pregnancy 11.5% 0 .05
VTE, Venous thromboembolism.
Table I. Distribution of admitted and ambulatory
patients and VTE diagnosis
Admitted to hospital Ambulatory treatment
DVT alone 1934 (85%) 335 (15%)
PE alone 882 (99%) 8 (0.89%)
DVT and PE 578 (98.2%) 10 (1.7%)
P  .001.
VTE, Venous thromboembolism; DVT, deep vein thrombosis; PE, pulmo-
nary embolism.
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Among surgical patients with VTE, 66% received pro-
phylaxis. Only 23% of immobilized patients presenting with
VTE had received prophylaxis. The doses and duration of
prophylactic low molecular weight heparin (LMWH) in
patients who developed VTE were 3824 units per day for
an average of 19.8 days for immobilized nonsurgical pa-
tients and 3870 units per day for 14.5 days in patients with
previous surgery. Venous thromboembolism was consid-
ered idiopathic in 46% of patients because risk factors were
not identified. Thrombophilia was sought in 18% of pa-
tients and identified in 35%. The distribution of risk factors
in patients with upper-extremity or leg DVT (without PE)
is shown in Table II. No significant differences were iden-
tified for varicose veins, travel, and pregnancy.
In the acute phase, during the first 10 days of treat-
ment, most patients received therapy with LMWH (88%);
485 were treated with unfractionated heparin (11%) and 35
with fibrinolysis (0.8%). Among patients with confirmed
PE, 24 (1.5%) received fibrinolysis. Cava filters were in-
serted in 85 patients (2%), of which 86% were permanent
and 14% removable. The main reasons for using filters in
this phase were high risk of bleeding (38%), recurrent VTE
(28.6%), bleeding during treatment (13%), and need for
surgery (11.7%). Pulmonary artery thromboembolectomy
was performed in 8 cases (0.02%). With respect to ambula-
tion, 63% of patients were kept at absolute bed rest, 31%
were allowed limited mobility, and 6% were fully ambu-
lated.
During the subsequent chronic phase of treatment
(secondary prevention), 2813 patients (74.8%) received
oral anticoagulants, 921 (24.5%) patients received LMWH,
and 26 (0.7%) received subcutaneous unfractionated hep-
arin. In this phase, 46 patients (1.3%) had cava filters
placed. The main reasons for filter placement were active
bleeding (36%), recurrent VTE (25%), need for surgery
(19.4%), and high risk of bleeding (8.3%). Elastic stockings
were prescribed for 1548 patients (53% of 2921, with
information about stocking use). The pharmacologic treat-
ment used in upper- and lower-extremity DVT is detailed
in Table III.
As of August 2002, 2408 patients had completed the
3-month follow-up and 1603 had not completed the fol-
low-up or the data were in the course of being uploaded.
During the 3-month follow-up period, 237 patients had
bleeding complications (9.8% of 2408 patients with com-
plete follow-up). Major hemorrhage occurred in 43.7% and
minor in 56.3% of patients with bleeding. In more than half
of these patients, bleeding was located in the gastrointesti-
nal or urinary tracts.
During the chronic treatment phase, 60% of bleeding
complications occurred in patients receiving oral antico-
agulants and 40% in patients receiving LMWH.
Recurrent VTE was diagnosed in 130 patients (5.5% of
2378 with complete follow-up information). Overall, 301
patients died during follow-up for different reasons (12.5%
of 2413 with complete information). Of these, 21 patients
died as a result of PE (7%) and 60 because of bleeding
problems (20%). Table IV details the proportion of adverse
events documented in patients with isolated DVT or with
PE (alone or with DVT). There was a significantly higher
incidence of death and bleeding in patients who were found
to have PE at presentation than in those who presented
with isolated DVT without concomitant PE.
DISCUSSION
To our knowledge, this registry is the largest prospec-
tive database collecting patients with confirmed VTE. As
there is not a selection process, all patients with DVT or PE
are included irrespective of the location of DVT, comorbid
conditions, prognosis, treatment, or outcome.
The RIETE initiative consists of a registry, and the data
reported are not from a prospective, randomized, con-
trolled trial. As in most similar registries,8,9,12-14 neither
diagnostic evaluations nor therapy are controlled. There-
fore, the strength of this ongoing registry is the prospective
collection of data reflecting real practice from a very large
sample of patients with documented VTE management in
hospitals throughout Spain.
There are several limitations of the RIETE registry that
should be acknowledged. First, the participating registry
hospitals are not necessarily representative of all Spanish
hospitals and probably reflect practice from physicians with
particular interest in VTE who volunteered to participate in
the registry. However, 40% of the participating hospitals
are the largest hospitals in Spain and responsible for the care
of approximately 25% of the Spanish population. This
could provide a good estimate of current clinical manage-
ment of VTE. Second, the registry is an observational
database, and accordingly, its value is to document practice
Table III. Pharmacologic treatment used in the acute
and chronic phases in patients with upper- and lower-
extremity deep vein thrombosis
Acute phase Upper-extremity Lower-extremity P
LMWH 91% 93% .3
Unfractionated heparin 7% 6.3% .9
Fibrinolysis 2% 0.2% .001
Chronic phase Upper-extremity Lower-extremity P
LMWH 43.8% 28% .001
Unfractionated heparin 0 0.2% .001
Oral anticoagulation 56% 71.4% .001
LMWH, Low–molecular weight heparin.
Table IV. Rates of adverse events in patients with
isolated DVT or with PE (alone or with DVT)
DVT alone PE ( DVT) P
Death 10.6% 14.8% .03
Recurrent VTE 6.5% 5.2% .7
Bleeding 8.5% 11.7% .01
DVT, Deep vein thrombosis; PE, pulmonary embolism; VTE, venous
thromboembolism.
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patterns and temporal trends rather than to compare out-
comes of patient subgroups. The main interest of this study
is to provide information on current “real world” practice,
which may be important to recognize gaps between infor-
mation obtained from clinical trials and real practice.
The age of patients in our registry is similar to the age
reported in other series from Sweden,1 France,2 and the
United States.8 With respect to the distribution of DVT
and PE in our series, it matches the distribution reported in
a recent French population-based study2 with 627 patients,
where 67% had isolated DVT, 14% had isolated PE, and
19% had DVT and PE. An interesting finding has been the
low rate of patients admitted to hospital for other reasons at
the time of VTE diagnosis (6.6%), which indicates that
most patients are at home (or discharged from hospital)
when VTE occurs.
Data on diagnostic testing reflect the relative use of
these tests in cases with confirmed VTE, but they do not
provide any information regarding their accuracy. The use
of ultrasound scans in 86% of patients for the diagnosis of
DVT is in agreement with published reports that demon-
strate that this test is very reliable for the diagnosis of
symptomatic DVT.15,16 Venography was used in 36% of
patients with confirmed upper-extremity thrombosis. This
invasive test remains the most valuable diagnostic tool for
this problem, although experience with noninvasive tech-
niques, such as duplex ultrasound scanning, is rapidly
evolving. The low incidence of calf DVT in this study could
be attributed to the fact that most early calf thrombi are
initially asymptomatic. Those thrombi progressing to prox-
imal veins are responsible for most of the symptoms.
Most patients underwent lung scintigraphy (perfusion
or ventilation-perfusion scans) for PE diagnosis. The results
of this test in our patients, with 62% high-probability scans,
is slightly lower than the 77% reported by the International
Cooperative Pulmonary Embolism Registry (ICOPER)
registry.12 The recent advent of spiral or helical CT is
gradually replacing pulmonary angiography, and data from
our registry reflect this new approach.17 D-dimer testing
was negative in almost 8% of patients with confirmed VTE
(sensitivity 92%). These results are similar to other reports
that show sensitivities between 80% and 95% for agglutina-
tion techniques and up to 97% for ELISA testing.18
The high proportion (46%) of VTE patients without
detectable thrombosis clinical risk factors is similar to the
50% reported by Cogo in Italy in a group of symptomatic
DVT outpatients.19 The risk factors more frequently found
in our patients were immobility, cancer, previous VTE, and
recent surgery, which are comparable with the factors re-
ported in population-based series from Sweden1 and the
United States.20
Two thirds of patients with VTE and recent surgery and
less than one quarter of nonsurgical immobilized patients
who were bedridden received prophylaxis. This indicates
that prophylaxis failed in many surgical patients and that
most nonsurgical patients at risk do not receive any prophy-
laxis. The problem of low implementation of prophylaxis in
surgical patients has been reported recently by other inves-
tigators from the United States21,22 and Brazil.14 On the
basis of these data, quality improvement should emphasize
the importance of implementing more intensive prophy-
laxis among high-risk patients.
A surprisingly low number of patients received inferior
vena cava filters (2%), which is noticeably lower than the
18% reported for patients with DVT in Boston8 or the 10%
from the ICOPER study in patients with PE.12 In the only
randomized study of filter placement in patients with iso-
lated proximal DVT,23 the device did not prolong survival
after a first episode of DVT, although it reduced the rate of
PE. This benefit was offset by a higher recurrent DVT rate.
During the initial acute treatment phase, most patients
received LMWH, as these heparin fragments have become
the standard therapy for VTE in most European countries
and North America. Yet, we were surprised by the high
proportion of patients who were admitted to the hospital
for VTE treatment, despite evidence supporting the home
treatment of both DVT and PE.7,24-26 However, it is
possible that a few patients with isolated DVT could have
been discharged from the emergency department in some
of the participating hospitals for ambulatory treatment.
Therefore, the actual percentage of patients with isolated
DVT being admitted to hospital could be lower.
We estimate that almost 25% of patients included in the
registry had underlying conditions or comorbidities (recent
bleeding, cancer, pregnancy, and renal failure) that put
them at risk to develop bleeding complications. This could
explain the high rate of patients—56% of upper-extremity
DVT and 71% of lower-extremity DVT—who received
secondary prophylaxis with LMWH instead of oral antico-
agulation. Besides, these fractionated heparins are also safe
and effective for the long-term treatment of these difficult
cases.
Another significant gap between published studies and
current practice in the registry hospitals was the high pro-
portion of VTE patients who were kept bedridden. Accord-
ing to the results of two prospective studies, early ambula-
tion is safe to recommend as routine in most DVT
patients.27,28
The incidence of adverse events during the 3-month
follow-up period is similar to the rates reported by Pran-
doni et al29 in a prospective cohort study of patients with a
first episode of symptomatic DVT. The incidence of bleed-
ing complications and recurrent VTE in that study was
9.8% and 4.9% 3 months after DVT diagnosis. In our
registry, these events were reported in 9.8% and 5.5% of
patients, respectively. Major bleeding occurred in 4% of
patients in our series, which is slightly higher than the .5%
to 3% reported in controlled trials, where some high-risk
patients were excluded.30 The mortality rate in our patients
(12.5% at 3 months) is lower than the 14% in-hospital
mortality rate from a Japanese registry of patients with PE31
and 17.4% from the ICOPER study.12 In our patients, only
25% of deaths were attributed to VTE or bleeding compli-
cations and most patients died from reasons unrelated to
VTE. This has also been reported by another study that
indicated that 15% of deaths in patients with suspected PE
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were attributable to PE.32 Factors associated with adverse
outcome are cancer, heart failure, previous VTE, hypoten-
sion, and hypoxemia.33 Other studies have suggested that
patients who are initially found to have PE have a higher
risk of developing recurrent pulmonary embolism com-
pared with patients with DVT alone.10,34,35 Although in
our patients the rate of recurrent VTE was similar in pa-
tients with DVT and PE, the incidence of mortality and
bleeding complications during the 3-month follow-up was
significantly higher in patients with confirmed PE (with or
without DVT) than in patients with isolated symptomatic
DVT. It is important to notice that in this registry, the
incidence of adverse events reflects early symptomatic prob-
lems developing within 3 months of VTE diagnosis. A
longer follow-up would probably increase the incidence of
VTE recurrences, bleeding complications, and mortality.
On the basis of the initial success of our registry, with
more patients enrolled than we initially anticipated, an
international registry could be organized with a similar
structure to undertake a more representative investigation
of unselected patients with VTE, to elucidate the risk factor
profiles for this disorder, and to find predictors for the
outcome of a thromboembolic event in different types of
patients.
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lona), J. .I Arcelus, J. Trujillo (Ma´laga), R. Barba, I Candel,
J. del Toro, C. Cervera, C. Ferna´ndez Capita´n, P. Rondo´n,
C. Sua´rez (Madrid), J. L. Beato (Albacete), A. Blanco, L.
Lo´pez (Co´rdoba), T. Bosch (Palma de Mallorca), J. Bosco,
P. Gallego, M.J. Soto (Ca´diz), F. Gabriel, E. Grau, P.
Roma´n, J.A. Todolı´ (Valencia), F. Garcı´a Bragado, S. Soler
(Girona), J.A. Gonza´lez-Fajardo (Valladolid), S. Herrera,
M.A. Page (Murcia), J.M. Llaneza, J. Lo´pez, I. Lo´pez, S.
Rubio (Asturias), J. Lasierra (Logron˜o), J.L. Lobo (Vito-
ria), P. Lo´pez-Beret (Toledo), A. Maestre, S. Reus (Ali-
cante), C. Panizo, A.L. Sampe´riz, G. Tiberio (Navarra), J.
Portillo (Ciudad Real), J. Montes (Vigo), J. Moreno (Seg-
ovia), J.A. Nieto (Cuenca), R. Otero (Sevilla), J.L. Pe´rez
Burkhardt (Tenerife), J. Rodrı´guez (Gran Canaria), D.
Sa´nchez (Avila), JF. Sa´nchez (Ca´ceres), A. Sa´nchez
(Salamanca), R. Segura (Corun˜a), F. Uresandi (Bilbao), R.
Valle (Santander), and F. Pajuelo (Medical Department,
Aventis Pharma, Madrid).
We express our gratitude to “S & H Medical Science
Service” for its logistic and administrative support.
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